BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 16128863)

  • 1. Glucagon-like peptide-1 reduces the pulsatile component of testosterone secretion in healthy males.
    Jeibmann A; Zahedi S; Simoni M; Nieschlag E; Byrne MM
    Eur J Clin Invest; 2005 Sep; 35(9):565-72. PubMed ID: 16128863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
    Nauck MA; Walberg J; Vethacke A; El-Ouaghlidi A; Senkal M; Holst JJ; Gallwitz B; Schmidt WE; Schmiegel W
    Regul Pept; 2004 Apr; 118(1-2):89-97. PubMed ID: 14759561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect.
    Prigeon RL; Quddusi S; Paty B; D'Alessio DA
    Am J Physiol Endocrinol Metab; 2003 Oct; 285(4):E701-7. PubMed ID: 12773303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lack of effect of exendin-4 and glucagon-like peptide-1-(7,36)-amide on insulin action in non-diabetic humans.
    Vella A; Shah P; Reed AS; Adkins AS; Basu R; Rizza RA
    Diabetologia; 2002 Oct; 45(10):1410-5. PubMed ID: 12378382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects.
    Steinert RE; Poller B; Castelli MC; Friedman K; Huber AR; Drewe J; Beglinger C
    Clin Pharmacol Ther; 2009 Dec; 86(6):644-50. PubMed ID: 19727071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide 2 inhibits ghrelin secretion in humans.
    Banasch M; Bulut K; Hagemann D; Schrader H; Holst JJ; Schmidt WE; Meier JJ
    Regul Pept; 2006 Dec; 137(3):173-8. PubMed ID: 16928403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs.
    Nishizawa M; Moore MC; Shiota M; Gustavson SM; Snead WL; Neal DW; Cherrington AD
    Am J Physiol Endocrinol Metab; 2003 May; 284(5):E1027-36. PubMed ID: 12569088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No increased risk of hypoglycaemic episodes during 48 h of subcutaneous glucagon-like-peptide-1 administration in fasting healthy subjects.
    Lerche S; Soendergaard L; Rungby J; Moeller N; Holst JJ; Schmitz OE; Brock B
    Clin Endocrinol (Oxf); 2009 Oct; 71(4):500-6. PubMed ID: 19094067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
    Meier JJ; Gethmann A; Nauck MA; Götze O; Schmitz F; Deacon CF; Gallwitz B; Schmidt WE; Holst JJ
    Am J Physiol Endocrinol Metab; 2006 Jun; 290(6):E1118-23. PubMed ID: 16403774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
    Meier JJ; Nauck MA; Pott A; Heinze K; Goetze O; Bulut K; Schmidt WE; Gallwitz B; Holst JJ
    Gastroenterology; 2006 Jan; 130(1):44-54. PubMed ID: 16401467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced glucagon-like peptide-1 (GLP-1) response to oral glucose in glucose-intolerant HIV-infected patients on antiretroviral therapy.
    Andersen O; Haugaard SB; Holst JJ; Deacon CF; Iversen J; Andersen UB; Nielsen JO; Madsbad S
    HIV Med; 2005 Mar; 6(2):91-8. PubMed ID: 15807714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection.
    Bendet N; Scapa E; Cohen O; Bloch O; Aharoni D; Ramot Y; Weiss M; Halevi A; Rapoport MJ
    Scand J Gastroenterol; 2004 Jul; 39(7):650-6. PubMed ID: 15370686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucagon-like peptide 1 increases mass but not frequency or orderliness of pulsatile insulin secretion.
    Pørksen N; Grøfte B; Nyholm B; Holst JJ; Pincus SM; Veldhuis JD; Schmitz O; Butler PC
    Diabetes; 1998 Jan; 47(1):45-9. PubMed ID: 9421373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in glucagon-like peptide-1 (GLP-1) secretion after biliopancreatic diversion or vertical banded gastroplasty in obese subjects.
    Valverde I; Puente J; Martín-Duce A; Molina L; Lozano O; Sancho V; Malaisse WJ; Villanueva-Peñacarrillo ML
    Obes Surg; 2005 Mar; 15(3):387-97. PubMed ID: 15826475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated plasma levels of glucagon-like peptide-1 after oral glucose ingestion in patients with pancreatic diabetes.
    Hiroyoshi M; Tateishi K; Yasunami Y; Maeshiro K; Ono J; Matsuoka Y; Ikeda S
    Am J Gastroenterol; 1999 Apr; 94(4):976-81. PubMed ID: 10201468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP.
    Theodorakis MJ; Carlson O; Michopoulos S; Doyle ME; Juhaszova M; Petraki K; Egan JM
    Am J Physiol Endocrinol Metab; 2006 Mar; 290(3):E550-9. PubMed ID: 16219666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of growth hormone on high plasma levels of glucagon-like peptide-1 (GLP-1) in hypophysectomized rats.
    Tateishi K; Kitayama N; Ishikawa H; Mitsudome A; Hirose S
    Exp Clin Endocrinol Diabetes; 2002 Oct; 110(7):361-3. PubMed ID: 12397536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired circulating glucagon-like peptide-1 response to oral glucose in women with previous gestational diabetes.
    Forbes S; Moonan M; Robinson S; Anyaoku V; Patterson M; Murphy KG; Ghatei MA; Bloom SR; Johnston DG
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):51-5. PubMed ID: 15638870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels.
    Johnson KM; Edgerton DS; Rodewald T; Scott M; Farmer B; Neal D; Cherrington AD
    Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1085-91. PubMed ID: 17684104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.